NCT07890324: A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
- State
- Not started
- Phase
- Phase 2
- People
- 96 planned
- Started
- Dec 2026
- Primary completion
- Aug 2027
- Arms
- 4 mg SXRN, 6 mg SXRN
- Results
- None posted
- 22 Oct 2026: Trial registered